Medical Devices & Pharmaceuticals in Johor: EIA, Sterilisation Effluent, Scheduled Wastes & JS-SEZ Incentives Guide

Medical devices and pharmaceuticals are among the priority golden sectors that the Johor-Singapore Special Economic Zone (JS-SEZ) actively promotes. Sites cluster in Iskandar Puteri’s technology parks, Nusajaya and Senai. The sector spans single-use sterile catheter production, implant fabrication and active-pharmaceutical-ingredient (API) fermentation and synthesis. Its compliance focus rests on uninterrupted clean-room HVAC power, on the deep treatment of trace aldehydes and phenols in chemical sterilisation effluent, and on the segregated disposal of pharmaceutical and clinical wastes.

EIA exposure depends on the process. Active-pharmaceutical-ingredient (API) chemical synthesis falls within the chemical-production thresholds of the Second Schedule under the Environmental Quality (Prescribed Activities) (Environmental Impact Assessment) Order 2015, made under section 34A of the Environmental Quality Act 1974 (Act 127), and requires a full EIA report to DOE headquarters with a public display before construction. By contrast, downstream sterile medical-device work — drawing, assembly and cleanroom packaging of catheters, syringes or sutures — is generally not a prescribed EIA activity, and instead requires prior written notification to the DOE of the installation and of the air- and effluent-treatment plan under the relevant regulations.

Sterile cleaning and pipework sterilisation discharge chemical effluent containing formaldehyde, free chlorine and acid-alkali cleaning agents, governed by the Environmental Quality (Industrial Effluent) Regulations 2009 [P.U.(A) 434/2009]. Because trace biocides are strongly cytotoxic and damage the activated sludge in a conventional biological system, the industrial effluent treatment system (IETS) typically needs an upstream advanced-oxidation (AOP) or activated-carbon adsorption stage to eliminate residual organic load. Standard A applies where the discharge point lies upstream of a gazetted water catchment; Standard B applies otherwise.

Medical and pharmaceutical production generates expired chemicals, off-specification drug materials, clinical wastes and IETS treatment sludge, regulated by the Environmental Quality (Scheduled Wastes) Regulations 2005 [P.U.(A) 294/2005]. These must be held in sealed, protective containers and must never be mixed into municipal waste or discharged into ordinary sewers. On-site storage is limited to 180 days or less; pharmaceutical and clinical wastes are typically rendered innocuous by high-temperature incineration at a contractor holding the relevant DOE prescribed-premises licence, with all transfers declared through the DOE e-Consignment system.

Medical-device and high-tech pharmaceutical plants demand exceptional voltage stability and supply continuity. Under the Electricity Supply Act 1990 (Act 447), the single-line diagram signed by a registered Professional Engineer is submitted to the Energy Commission (Suruhanjaya Tenaga, ST). Critical production and HVAC control systems must have full immunity to momentary voltage sags, so plants install online UPS and standby diesel generators; for projects above roughly 1000 kVA, reserving land for a dual-chamber 11 kV PE substation with a dual-feed supply is recommended. Qualifying new investments in medical devices and pharmaceuticals may apply to MIDA for the JS-SEZ special corporate-tax rate, as set out below.